Clinical Trials
10 trialsNCT04955743 2026-06-04
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT05103904 2026-04-24
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
Phase 2 Terminated
NCT06114940 2026-03-05
PLUTO
Jinling Hospital, China
Phase 2 Terminated
NCT05263492 2025-10-02
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT04729348 2025-07-25
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Terminated
NCT04267120 2025-03-21
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Washington University School of Medicine
Phase 2 Terminated
NCT03506048 2022-11-10
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
Emory University
Phase 2 Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03433703 2019-12-06
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
Eisai Inc.
Phase 2 Terminated
NCT02657369 2019-10-15
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Eisai Inc.
Phase 2 Terminated